Prior statin use ups survival after cardiac arrest
Statins, when taken before cardiac arrest, improve 1-year survival outcomes, a recent study has found.
Accessing the medical records of 142,131 adults with a nontraumatic cardiac arrest, researchers identified those who had (n=4,028; mean age, 69.5±11.8 years; 57.5 percent male) and had not (n=138,103; mean age, 68.1±17.6 years; 63.2 percent male) taken statins 30 days before the cardiac arrest event. The primary clinical outcome was 1-year survival.
Propensity-score matching was performed to reduce selection bias; the resulting groups were comparable in terms of sex, urbanization and most comorbidities. In the matched cohort, those who took statins showed significantly better survival to admission (21.1 percent vs 17.2 percent; p<0.0001) and to hospital discharge (6.1 percent vs 4.3 percent; p<0.0001).
One-year survival was also significantly better in patients who received statins 30 days before the cardiac arrest event (4.8 percent vs 3.2 percent; p<0.0001). This was confirmed by Kaplan-Meier survival analysis, which showed better survival through the 1-year observation period (log-rank p<0.0001).
Logistic regression analysis further identified prior use of statins as an important factor for higher odds of 1-year survival, which remained significant even after adjustments for other independent predictors (odds ratio [OR], 1.41; 95 percent CI, 1.16–1.71; p=0.001).
The significant survival benefit was consistent in patients who used high-potency (rosuvastatin ≥10 mg; n=1,150; OR, 1.42; 1.04–1.94; p=0.028) and low-potency (atorvastatin ≥20 mg, including all other statins; n=2,878; OR, 1.43; 1.15–1.79; p=0.002) statins.